Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Agios Pharmaceuticals (AGIO) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $129.7 million.

  • Agios Pharmaceuticals' Operating Expenses rose 1608.05% to $129.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $520.4 million, marking a year-over-year increase of 1830.95%. This contributed to the annual value of $462.2 million for FY2024, which is 1050.06% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Operating Expenses stood at $129.7 million, which was up 1608.05% from $139.5 million recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Operating Expenses peaked at $139.5 million during Q2 2025, and registered a low of $91.2 million during Q3 2021.
  • Moreover, its 5-year median value for Operating Expenses was $103.5 million (2022), whereas its average is $107.7 million.
  • Examining YoY changes over the last 5 years, Agios Pharmaceuticals' Operating Expenses showed a top increase of 32327.37% in 2021 and a maximum decrease of 2998.93% in 2021.
  • Over the past 5 years, Agios Pharmaceuticals' Operating Expenses (Quarter) stood at $104.8 million in 2021, then dropped by 1.28% to $103.5 million in 2022, then grew by 9.56% to $113.4 million in 2023, then increased by 19.75% to $135.8 million in 2024, then fell by 4.43% to $129.7 million in 2025.
  • Its Operating Expenses stands at $129.7 million for Q3 2025, versus $139.5 million for Q2 2025 and $115.4 million for Q1 2025.